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Background: A rapid and sensitive ultraviolet-visible (UV-VIS) spectroscopic method was developed for the estimation
of pyrimidine derivative 6-Bromo-3-(6-(2,6-dichlorophenyl)-2-(morpolinomethylamino) pyrimidine4-yl) -2H-chromen-2-
one (BT10M) in bulk form.
Results: Pyrimidine derivative was monitored at 275 nm with UV detection, and there is no interference of diluents at
275 nm. The method was found to be linear in the range of 50 to 150 μg/ml. The accuracy and precision were
determined and validated statistically. The method was validated as a guideline.
Conclusions: The results showed that the proposed method is suitable for the accurate, precise, and rapid
determination of pyrimidine derivative.
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Nitrogen containing heterocyclic ring such as pyrimi-
dine is a promising structural moiety for drug design.
Pyrimidine derivatives form a component in various
useful drugs and are associated with many biological
and therapeutic activities. Condensed pyrimidines have
been reported as antimicrobial [1-3], anti-inflammatory
[4,5], analgesic [6,7], anticancer [8-10], anti-HIV [11],
antitubercular, antimalarial, diuretic, and cardiovascular
disease [12] (Scheme 1).
The present work is a synthesis, a biological evalu-
ation and validation of novel pyrimidine derivatives. Re-
search workers have synthesized 50 pyrimidine derivatives
(T1M-T10M, T1P-T10P, BT1M-BT10M, BT1P-BT10P,
CT1M-CT5M, and CT1P-CT5P). Among them, BT10M
exhibited maximum antimicrobial, anti-inflammatory,
and analgesic activity. Hence, a validation study was
done on BT10M. BT10M is chemically [6-Bromo-3-(6-(2,6-
dichlorophenyl)-2-(morpolinomethylamino) pyrimidine4-* Correspondence: anshu_17oct@yahoo.co.in
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in any medium, provided the original work is pyl) -2H-chromen-2-one]. It is a yellow crystalline powder
with a molecular formula of C24H19BrCl2N4O3 and a
molecular weight of 562.24. It is a potent antimicrobial,
analgesic and anti-inflammatory agent among all the
synthesized derivatives. Hence, the aim of present in-
vestigation is to develop a simpler, rapid, and cost-
effective analytical method for the determination of
pyrimidine derivative (BT10M) in bulk dosage form
suitable for routine quality control analysis.
Method validation is the process used to confirm that
analytical procedure employed for a specific test is suitable
for its intended use. It is an integral part of any good ana-
lytical practice. Methods need to be validated or revali-
dated [13].Methods
Chemical and reagent
BT10M was synthesized by research workers and then
validated. Methanol and acetonitrile (1:1) were used
throughout spectrophotometric method development
and validation.s is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Scheme 1 Chemical structure of BT10M.
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The method was performed on a double-beam ultraviolet-
visible (UV-VIS) spectrophotometer (Shimadzu model
1700 (Shimadzu, Kyoto, Japan)) having two matched
quartz cells with a 1-cm light path.
Determination of maximum wavelength (λmax),
methodology, and sample preparation
About 50 mg of BT10M was weighed accurately and
transferred into a 50-ml volumetric flask and dissolvedTable 1 Validation summary
Serial number Parameters Acceptanc
01 Precision
(a) System precision %RSD NMT 1.5%
(b) Method precision %RSD NMT 1.5%
02 Specificity No conside
componen
or at detec
03 Accuracy (by recovery)
% Recovery 100% ± 2%
%RSD NMT 1.5%
% Deviation from accuracy ±1.5%
04 Linearity Coefficient
(r2) NLT 0.9
05 Ruggedness %RSD: NMT
06 Robustness %RSD: NMT
07 Limit of detection and limit of quantitation LOD
LOQ
NMT, not more than; NLT, not less than.in 25 ml of methanol and acetonitrile (1:1) and made
up to the volume with the same solvent mixture to give
a standard concentration of 1,000 μg/ml. Transfer 5 ml
of above solution into the 50-ml volumetric flask, di-
lute, and made up to the volume with the same solvent
mixture to get a standard concentration of 100 μg/ml.
This solution was scanned against a blank over the en-
tire UV-VIS wavelength of 200 to 400. Based on the




rable absorbance of any other
t of formulation at λmax of analyte
tion wavelength






of correlation r2: 0.997
98
1.5% %RSD: 0.1572




Figure 1 Linearity plot. The BT10M absorbance response in the concentration range of about 50 mcg/ml to 150 mcg/ml was found to be linear
to the analyte concentration in the solution with a correlation coefficient (r2) of 0.997.
Table 2 Linearity table of BT10M in working standard
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The method was validated with respect to linearity, ac-
curacy, precision, specificity, robustness, ruggedness,
LOD, and LOQ in Table 1.
Discussion
The method was validated with respect to linearity, ac-
curacy, precision, specificity, robustness, ruggedness,
LOD, and LOQ. The method was established according
to the International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceu-
ticals for Human Use (ICH) guidelines. BT10M exhib-
ited maximum absorption at 275 nm and obeyed Beer's
law in the concentration range of 50 to 150 μg/ml. The
proposed method for the determination of BT10M
showed linear regression y = 0.005x + 0.025 with a coef-
ficient correlation (r2) of 0.997 (Figure 1). The precision
was determined by the relative standard deviation of
the six-assay sample of BT10M, and the assay of each
was calculated and the obtained relative standard devi-
ation of % assay was less than 1.5%. The percentage re-
covery for BT10M was found in the range of 98.97% to
99.83% which indicates that the developed method was
simple, rapid, and precise. LOD was found to be 145.2
and limit of quantitation to be 440.0. The proposed
method will be suitable for the analysis of newly syn-




The methods were validated with respect to linearity,
accuracy, precision, specificity, ruggedness, robustness,
limit of detection (LOD), and limit of quantitation
(LOQ).Linearity
The linearity of an analytical method is its ability to
elicit test results that are directly, or by a well-defined
mathematical transformation, proportional to the con-
centration of analyte in the samples within a given
range. For assay determination, the concentration of
BT10M is 100 μg/ml. So the working range of analyte
was set between 50, 62.5, 75, 87.5, 100, 112.5, 125,
137.5 and 150 μg/ml to show the linearity of the curve
obtained. The observations and calibration curve are
shown in Table 2 and Figure 1.
Accuracy (by recovery test)
Accuracy of method is by shown by recovery study and
spiking working standard in the placebo at levels 80%,
100%, and 120% of the working standard. Recovery
study was performed by spiking in BT10M to the pla-
cebo at levels 80%, 100%, and 120% of working stand-
ard. The samples were prepared according to the assay
procedure. The results are shown in Tables 3 and 4.
Table 3 Accuracy reading
Level (Approximate) Standard added (mg) Absorbance at 275 nm Standard recovered (mg) %Recovery Mean recovery %RSD
80% 40.5 0.458 40.43 99.83 99.37% 0.4366
0.451
0.459
100% 50.8 0.567 50.28 098.97
0.561
0.574
120% 60.1 0.670 59.68 099.30
0.676
0.673
Table 5 System precision data of BT10M working
standard solution
Serial number Absorbance at 275 nm
1 0.566
2 0.565
Chaudhary et al. Organic and Medicinal Chemistry Letters 2014, 4:15 Page 4 of 6
http://www.orgmedchemlett.com/content/4/1/15The percentage recovery for BT10M was found in the
range of 98.97% to 99.83% with an overall relative
standard deviation (%RSD) of 0.4366. From the data ob-
tained which was given in Table 3, the method was
found to be accurate. Formula of standard deviation
was SD = (xi − x/n − 1)1/2 if n is very large. In case of
very small data, SD = (xi − x/n)1/2.
Precision
The precision of an analytical method is the degree of
agreement among individual test results when the
method is applied repeatedly to multiple sampling of
homogenous sample. The precision of an analytical
method is usually expressed as the standard deviation
or relative standard of a series of measurements. Assay
preparation and standard preparation were prepared
as per method of analysis of six BT10M assay sample
preparations as per the experimental conditions in
method of analysis. Calculated percent of BT10M in
each assay sample percent by spectrophotometry and
the results and observation are summarized in Tables 5
and 6.
Assay


















80% 080.75 081.9289 101.46 +01.46
100% 100.40 099.6269 099.23 −00.77
120% 121.05 120.6626 099.68 −00.32The precision will be determined by the relative
standard deviation of the six-assay sample of BT10M,
and the assay of each is calculated and the obtained
relative standard deviation of % assay should be less
than 1.5%. The %RSD shows that precision of the
method was satisfactory.
Specificity
Specificity study is designed to prove that the BT10M in
the solution gives maximum absorbance at wavelength
275 nm, and there is no interference from the solvent.
The purpose of this study is to establish the fact that
inherent chemical stability of the molecule remains in-
tact during its existence. If any degradation product
formed, it can be monitored and resolved to quantify
the nature and extent of degradation. For this, the
spectrum of BT10M, placebos are studied. The sample
preparation is as per methodology. The spectrum of
BT10M is shown in Figure 2.
For the spectrophotometric method, no other compo-
nent of formulation shows considerable absorbance at
the λmax of the analyte or at the detection wavelength
of the subject analyte. In this case of BT10M, the detec-
tion wavelength is 275 nm. The placebo solution under







Weight of BT10M WS = 50.0 mg.
Table 6 Method precision data for estimation of BT10M
Assay Sample weight (mg) Absorbance % Assay
1 50.2 0.576 101.75
2 50.4 0.576 101.29
3 50.2 0.572 101.02
4 50.8 0.580 101.22
5 50.0 0.569 100.96
6 50.7 0.579 101.37
Average 101.2683
%RSD 0.27995
Table 7 System precision data of BT10M working
standard solution









Weight of BT10M: 49.8 mg.
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The ruggedness of the analytical method is the degree
of reproducibility of test results obtained by the analysis
of the sample on different days, by different chemist
using different instruments. In this study, two individ-
ual assay sample preparations of BT10M drug product
were prepared by different chemists for analysis. Six (6)
replicate observations of the same standard solution
were obtained as well as six observations of different
sample solution were recorded. The assay percentage of
each sample was calculated in each case. The results
are summarized in Tables 5, 6, 7, 8, 9.
The ruggedness (inter-day precision) will be deter-
mined by the relative standard deviation of the results
of assay of two different chemists on different days.
Robustness
The robustness of an analytical method is a measure of
its capacity to remain unaffected by small but deliberate
variations in method parameters and provides an indi-
cation of its reliability under normal usage. Method ro-
bustness was determined by analyzing the same sample
at normal operating conditions and also by changingFigure 2 Spectrum of BT10M.some operating analytical conditions. The result and
observation are summarized in Table 10.
The robustness will be determined by the relative
standard deviation of the results of assay of two differ-
ent conditions by a change in original parameter.
Limit of detection and limit of quantitation
Limit of detection LOD is defined as the lowest con-
centration of an analyte in a sample that can be de-
tected, not quantified.
Limit of quantitation The lowest concentration of an
analyte in a sample that can be determined with accept-
able precision and accuracy under the stated oper-


























All the validation parameters for all the developed
methods were studied as per ICH guidelines. All theTable 8 Method precision data for BT10M
Assay Sample weight (mg) Absorbance % Assay
1 50.2 0.566 100.27
2 50.5 0.572 100.73
3 50.8 0.582 101.94
4 50.7 0.578 101.45
5 50.2 0.568 100.64
6 50.9 0.579 101.23
Average 101.0433
%RSD 0.6041
Table 9 Mean % assay and %RSD
Chemist A Chemist B Average %RSD
101.2683 101.0433 101.1558 0.1572
Table 10 Percentage deviation for sample under both
conditions
Parameter Original condition Changed conditions
Dilution medium Acetonitrile:methanol Acetonirile:methanol
1:1 1:2
Assay in % 101.98 100.44
% Deviation from mean
assay value obtained in
precision studies
+00.72 −00.82
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lective, precise, and reproducible. Hence, the method
can be used for routine analysis of BT10M in bulk dos-
age form.Competing interests
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